Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Now, Nuvelo Will Go It Alone On Thrombolytic Alfimeprase

This article was originally published in The Pink Sheet Daily

Executive Summary

Development of the stalled anti-clotting agent resumes as partner Bayer pulls out of the collaboration.
Advertisement

Related Content

Nuvelo Discontinues Alfimeprase After Disappointing Efficacy Results
Nuvelo Discontinues Alfimeprase After Disappointing Efficacy Results
Nuvelo Begins Phase II Trial Of Thrombolytic For Ischemic Stroke
Nuvelo Begins Phase II Trial Of Thrombolytic For Ischemic Stroke
Nuvelo Restarts Alfimeprase Trial For Central Venous Catheter Occlusion
Nuvelo Restarts Alfimeprase Trial For Central Venous Catheter Occlusion
Nuvelo Discontinues Factor VIIa Inhibitor To Focus On Alfimeprase
Forest/Paion’s Desmoteplase Program In Question After Failed Stroke Trial
Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data
Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS066244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel